Across TCGA pan-cancer cohorts, GSTM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSTM2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTM2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GSTM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.472	0.248	<.001	86	view →
LUAD	OS	Tertile	All	0.919	0.589	<.001	39	view →
CCRCC	DFS	Quartile	III,IV	0.886	0.333	<.001	35	view →
UCEC	OS	Median	II,III,IV	0.609	1.000	.008	12	view →
HNSC	OS	Median	II,III,IV	0.933	0.992	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GSTM2 tumor-vs-normal RNA expression · all GSTM2 data types